![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, July 29, 2018 2:11:26 PM
https://www.equities.com/news/4-emerging-growth-biotech-names-for-the-next-generation
RS: We are covering CorMedix Inc. (CRMD:NYSE.MKT), with a Buy rating and price target of $6.50/share. It is a particularly interesting name because it is developing a next-generation anti-infective solution called Neutrolin (taurolidine + citrate + heparin) to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis.
The company has the FDA's qualified infectious disease product (QIDP) designation, which was enabled by the Generating Antibiotic Incentives Now (GAIN) Act that was signed into law by President Obama in mid-2012. In our view, the CorMedix solution embodies a characteristic that is absolutely critical in the world of novel anti-infective development, and that is the ability to evade resistance by microorganisms and bacteria. Effectively, the company is using a non-antibiotic compound with the main active ingredient taurolidine, which has been widely assessed as active against various infectious organisms. Taurolidine is not like an antibiotic, against which resistance will always evolve. We think this platform positions CorMedix particularly well going forward.
The company is developing taurolidine, in combination with citrate and heparin, to address the issue of catheter colonization by bacteria to form biofilms. You're looking at CRBSIs in patients in the hospital with catheters threaded into their arms or threaded via a central line so they can be fed nutrients, be given a chemotherapy drug, or undergo hemodialysis. The catheter can, inevitably really, become colonized by all kinds of nasty bugs. Using the taurolidine catheter lock solution allows the company to effectively eliminate the bacterial colonization of these catheters.
TLSR: Is the compound bacteriostatic, or is it specifically targeting the formation of biofilms?
RS: Taurolidine has been documented to prevent biofilm formation, which sets it apart from typical antibiotics, which are not effective against biofilms. This puts CorMedix and Neutrolin in a privileged position among anti-infective agents, because Neutrolin can be used broadly without fear that resistance will occur and render it useless.
In addition, because Neutrolin is focused specifically on the CRBSI domain, there is a clear hospital- and dialysis center-based setting for the product. We're not talking about a mass-market product with hundreds of nationwide reps needed in a marketing effort.
We should see interim data from the first of two Phase 3 trials with Neutrolin later this year.
Obviously, if those data are positive, we believe CorMedix could obtain a very lucrative marketing partnership in the U.S., and would potentially be able to accelerate sales of Neutrolin in non-U.S. territories, particularly in Europe, where the compound is approved and marketed in certain countries.
TLSR: Your implied market cap is only about $230M, and I'm assuming that's a 12–18 month price target. As I look at Neutrolin, I'm thinking every intensive care unit (ICU) should be using it because nosocomial (hospital-acquired) infections are something institutions are focusing on. I'm also thinking that all the nephrology/dialysis centers should be using it. And there are other opportunities for taurolidine, such as prevention of urinary tract infections (UTIs) and associated catheter encrustation. Your implied market valuation seems very low considering the potential, and the fact that there is no other FDA-approved product like this on the market. Can you comment on that?
RS: I don't disagree with you. We have a relatively conservative viewpoint here, and the potential future upside may well be significantly greater than what we have projected.
We are, first of all, assuming market penetration only in the domain of CRBSIs—not in UTIs or any medical device or suture-related use of taurolidine. We are also not giving the company significant credit for the commercialization of Neutrolin outside of the U.S. We are only modeling sales in the areas of hemodialysis, ICU patients, patients on oncology drugs administered via intravenous drip, and patients receiving total parenteral nutrition.
In addition, we are assuming a relatively modest market cap compared to the current valuations of other single-product companies in the anti-infective domain—those developing antibiotics against which resistance will inevitably occur.
CRMD-Europe
http://cormedix-europe.com/home-349.html
Investor 100
Recent CRMD News
- CorMedix Inc. Receives FDA Feedback on Potential Label Expansion • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath • GlobeNewswire Inc. • 06/06/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/23/2024 04:15:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:22:51 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/09/2024 09:06:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 12:00:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:40:17 AM
- CorMedix Inc. Announces CMS Grants TDAPA to DefenCath • GlobeNewswire Inc. • 04/19/2024 12:30:00 PM
- CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin) • GlobeNewswire Inc. • 04/15/2024 12:30:00 PM
- CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/12/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 10:26:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 01:11:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 01:10:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 01:09:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 01:04:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 01:39:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/14/2023 09:05:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 09:00:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:11:33 PM
- CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:35:11 PM
- CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference • GlobeNewswire Inc. • 10/11/2023 12:30:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM